drugset / Trial / NCT06873724
A Study of SPY003-207 in Healthy Volunteers
Phase 1
Active not recruiting
59 enrolled
Spyre Therapeutics, Inc.
Altasciences Company Inc. · collab
RandomizedSequentialQuadruple-blindBasic science
Summary
This is a Phase 1, randomized, double-blind, placebo-controlled, single dose, first in human safety, tolerability, and pharmacokinetic study of SPY003-207 in healthy participants.
Timeline
- Start
- 2025-03-10
- Primary completion
- 2026-11-18
- Completion
- 2026-11-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SPY003-207 | Unknown | — | — |
Indications
No indication recorded.